Fig. 8.
![Fig. 8. In vivo tracking of BCL1 tumor in the spleen. / HuCD64+ mice received 2 μg murine G-CSF/d subcutaneously 4 days before tumor and continuing throughout the course of therapy (10 days in total). Mice were then inoculated with 107 BCL1 tumor cells intraperitoneally on day 0 and were treated with twice daily injections of 50 μg BsAb intraperitoneally on days 1 to 5 (500 μg/mouse in total). One animal per group was killed on days 5, 10, and 15, and the percentages tumor cells in spleen were determined using flow cytometry with PE-labeled anti-Id versus FITC-labeled anti-CD22. Shown are dot plots from a representative mouse at days 10 and 15, treated with BsAb of the specificities indicated. Control BsAb was the nonbinding [huCD64 × A31 Id].](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/96/10/10.1182_blood.v96.10.3544/5/h82200347008.jpeg?Expires=1735514385&Signature=TT8mVE3iB0dt227jk6ax-m~Y8Ga-gJ0cRsALskiUis8Lsu2vCXejWFlIZmInagazAwUDo2jStimA1F4mr-m09612DUD8sqWh0jED7lXAwChZn0e1B798N7l8GFDdY3cEiaEsuj3kiFreY79Td8oqMPexndSe4Ia4wBx8N0pKZ~~TgxOgd5HVY2Xl-ePItsQSgUsBA8jo1dHbELh87xxUrwzIMa-TjD7WfN-86-mVx2Vh3upbEWe47yG~MvZjsya680OVn4UYthSSOPS1MWTRdLOOataNq8XgzQz48-4piA9Ntlv27Y335PgsFg~oDwjpkL2zwG61nHYHRLdmxBA55g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
In vivo tracking of BCL1 tumor in the spleen.
HuCD64+ mice received 2 μg murine G-CSF/d subcutaneously 4 days before tumor and continuing throughout the course of therapy (10 days in total). Mice were then inoculated with 107 BCL1 tumor cells intraperitoneally on day 0 and were treated with twice daily injections of 50 μg BsAb intraperitoneally on days 1 to 5 (500 μg/mouse in total). One animal per group was killed on days 5, 10, and 15, and the percentages tumor cells in spleen were determined using flow cytometry with PE-labeled anti-Id versus FITC-labeled anti-CD22. Shown are dot plots from a representative mouse at days 10 and 15, treated with BsAb of the specificities indicated. Control BsAb was the nonbinding [huCD64 × A31 Id].
